Outlook Therapeutics, Inc. (OTLK)
0.3511
+0.01
(+4.43%)
USD |
NASDAQ |
Mar 20, 16:00
0.35
0.00 (0.00%)
After-Hours: 20:00
Outlook Therapeutics Research and Development Expense (Quarterly) : 3.634M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 21.40M |
| Amicus Therapeutics, Inc. | 23.74M |
| CorMedix, Inc. | 8.60M |
| ACADIA Pharmaceuticals, Inc. | 84.76M |
| Alnylam Pharmaceuticals, Inc. | 372.22M |